DBV Technologies to Participate at Upcoming Investor Conferences
31 Agosto 2021 - 02:30AM
Montrouge, France, August 31, 2021
DBV Technologies to
Participate at Upcoming Investor
Conferences
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that DBV Technologies’
senior management team will participate in upcoming virtual
investor conferences in September.
Goldman Sachs Eleventh
Annual Biotech Symposium Company management will
participate in virtual investor meetings on September 7, 2021.
Citi’s
16th Annual
BioPharma
Virtual ConferenceCompany
management will participate in virtual investor meetings on
September 8, 2021.
H.C. Wainwright
23rd Annual Global Investment
ConferenceThe pre-recorded fireside chat will be available
on demand starting September 13, 2021 at 7:00 AM ET for the
duration of the conference.
A webcast of the fireside chat will be available
on the Investors & Media section of the Company’s website:
https://www.dbv-technologies.com/investor-relations/
A replay of the fireside chat will also be
available on DBV Technologies’ website after the event.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut. DBV Technologies has global headquarters in Montrouge,
France, and North American operations in Summit, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing one-half of one ordinary share)
are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024